Suppr超能文献

高通量激酶分析:一种发现新型激酶抑制剂的更有效方法。

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.

作者信息

Miduturu Chandrasekhar V, Deng Xianming, Kwiatkowski Nicholas, Yang Wannian, Brault Laurent, Filippakopoulos Panagis, Chung Eunah, Yang Qingkai, Schwaller Juerg, Knapp Stefan, King Randall W, Lee Jiing-Dwan, Herrgard Sanna, Zarrinkar Patrick, Gray Nathanael S

机构信息

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

出版信息

Chem Biol. 2011 Jul 29;18(7):868-79. doi: 10.1016/j.chembiol.2011.05.010.

Abstract

Selective protein kinase inhibitors have only been developed against a small number of kinase targets. Here we demonstrate that "high-throughput kinase profiling" is an efficient method for the discovery of lead compounds for established as well as unexplored kinase targets. We screened a library of 118 compounds constituting two distinct scaffolds (furan-thiazolidinediones and pyrimido-diazepines) against a panel of 353 kinases. A distinct kinase selectivity profile was observed for each scaffold. Selective inhibitors were identified with submicromolar cellular activity against PIM1, ERK5, ACK1, MPS1, PLK1-3, and Aurora A,B kinases. In addition, we identified potent inhibitors for so far unexplored kinases such as DRAK1, HIPK2, and DCAMKL1 that await further evaluation. This inhibitor-centric approach permits comprehensive assessment of a scaffold of interest and represents an efficient and general strategy for identifying new selective kinase inhibitors.

摘要

选择性蛋白激酶抑制剂仅针对少数激酶靶点开发。在此我们证明,“高通量激酶谱分析”是一种发现针对既定以及未探索激酶靶点的先导化合物的有效方法。我们针对一组353种激酶筛选了一个由118种化合物组成的文库,这些化合物构成两种不同的骨架(呋喃-噻唑烷二酮和嘧啶并二氮杂卓)。每种骨架都观察到了独特的激酶选择性谱。鉴定出了对PIM1、ERK5、ACK1、MPS1、PLK1 - 3和极光激酶A、B具有亚微摩尔细胞活性的选择性抑制剂。此外,我们还鉴定出了针对迄今未探索的激酶(如DRAK1、HIPK2和DCAMKL1)的强效抑制剂,有待进一步评估。这种以抑制剂为中心的方法允许对感兴趣的骨架进行全面评估,代表了一种识别新型选择性激酶抑制剂的有效且通用的策略。

相似文献

2
Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.利用CK2抑制剂库靶向DYRK和PIM激酶。
Biochim Biophys Acta. 2013 Jul;1834(7):1402-9. doi: 10.1016/j.bbapap.2013.01.018. Epub 2013 Jan 27.
9
Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.N-取代的7-氮杂吲哚作为PIM1激酶抑制剂的发现 - 第一部分。
Bioorg Med Chem Lett. 2017 Oct 15;27(20):4730-4734. doi: 10.1016/j.bmcl.2017.08.069. Epub 2017 Sep 18.

引用本文的文献

6
Human Polo-like Kinase Inhibitors as Antiplasmodials.人源 Polo 样激酶抑制剂作为抗疟药物。
ACS Infect Dis. 2023 Apr 14;9(4):1004-1021. doi: 10.1021/acsinfecdis.3c00025. Epub 2023 Mar 15.
8

本文引用的文献

7
PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.PIM 激酶抑制剂下调 STAT3(Tyr705)磷酸化。
Mol Cancer Ther. 2010 Sep;9(9):2478-87. doi: 10.1158/1535-7163.MCT-10-0321. Epub 2010 Jul 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验